For many of these, they have been asked to see their physician to see if the generic or the drug that is on NIHB can actually accommodate their need. We do know of two rare disease drugs that we won’t be able to change and those are very high-cost drugs. I think there will be some savings but it will only be in the case where the product can move to a generic, and in most cases the list got quite small. I think it is more on a go forward that we start to follow the set formulary, so there will be some costs, but it will be limited. Thank you.